Remyelinating antibody study data revealed

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Remyelinating antibody study data revealed

Postby MSUK » Thu Apr 23, 2015 12:13 am

Acorda Therapeutics Inc has presented data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

Safety data showed rHIgM22 was well-tolerated in each of the five tested doses, supporting additional clinical development. In addition, testing detected rHIgM22 in cerebrospinal fluid (CSF), indicating the drug’s access to the central nervous system..... Read More - http://www.ms-uk.org/myelin
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2876
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service